Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant enzyme produced within carrot cells. Its product pipeline also comprises PRX-106 or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is being developed as a treatment of certain immune diseases, such as rheumatoid arthritis, Chrohn’s disease, placque psoriasis, and other autoimmune disorders; and two additional undisclosed therapeutic proteins that are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. The company was founded in 1993 and is based in Carmiel, Israel.

Key Statistics